Alfons Grunenberg

This inventor holds 26 USPTO granted patents and 9 published patent applications, plus 15 CIPO patents and 15 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Adverio Pharma Gmbh, Bayer Intellectual Property Gmbh, Bayer Pharma Aktiengesellschaft. Active years: 1997-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alfons Grunenberg. Retrieved from https://idiyas.com/inventor/alfons-grunenberg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 9)

% Patents Active = 96.2

CIPO Patents = 15 (Patent Applications = 2)

EPO Patents = 15 (Patent Applications = 15)

Average Co-Inventor Count = 3.5

ph-index = 7

Forward Citations = 137(Granted Patents)

Location History:

Dormagen, DE (1997 - 2018)
Wuppertal, DE (2017 - 2024)

Company Filing History:

Bayer Intellectual Property Gmbh

patents

4 out of 387

Bayer Pharma Aktiengesellschaft

patents

4. 3 out of 12,268

Bayer Aktiengesellschaft

patents

5. 2 out of 53

Aicuris Gmbh + Co. Kg.

Bayer Animal Health Gmbh

Bayer Schering Pharma Ag

Years Active: 1997-2025

Loading Chart...

Areas of Expertise:

Pharmaceutical Ingredients

Crystalline Modifications

Drug Formulation

Purification Processes

Active Compounds

Antiviral Agents

Methyl Carbamate

Dihydroquinazoline Derivative

Hydrochloride Trihydrate

Pyrazolopyridines

Carboxamide Compounds

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12503469 - Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate (2025-12-23),

2. RE49860 - Process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and purification thereof for use as pharmaceutical active ingredient (2024-03-05),

3. RE49575 - Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-l,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient (2023-07-10),

4. 11203593 - Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate (2021-12-21),

5. 10662188 - Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate (2020-05-26),

6. 10633356 - Hydrates of substituted 5-fluoro-1H-pyrazolopyridines (2020-04-28),

7. 10399977 - Process for preparing (4S)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and purification thereof for use as a pharmaceutical active ingredient (2019-09-03),

8. 10364229 - Crystalline substituted 5-fluoro-1H-pyrazolopyridines and process for preparing (2019-07-30),

9. 10087183 - Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1h-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate (2018-10-02),

10. 10059707 - Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro- 1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient (2018-08-28),

11. 9957232 - 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate (2018-05-01),

12. 9637459 - Sodium and calcium salts of dihydroquinazoline derivative and use thereof as antiviral agents (2017-05-02),

13. 9604948 - Process for preparing substituted 5-fluoro-1H-pyrazolopyridines (2017-03-28),

14. 9340535 - N-[5-(Aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate (2016-05-17),

15. 8877933 - Thermodynamically stable form of a tosylate salt (2014-11-04),

Title: The Innovative Journey of Alfons Grunenberg: Pioneering Pharmaceutical Advancements

Introduction:

Alfons Grunenberg, a prolific inventor based in Wuppertal, DE, has left an indelible mark in the field of pharmaceuticals through his innovative creations. With a commitment to excellence and a passion for pushing boundaries, Grunenberg's contributions have revolutionized the way we approach pharmaceutical active ingredients.

Latest Patents:

Grunenberg's notable patent, "Process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and purification thereof for use as pharmaceutical active ingredient," stands as a testament to his expertise in developing novel processes for essential pharmaceutical components.

Career Highlights:

Having secured 1 patent, Alfons Grunenberg is associated with Bayer Pharma Aktiengesellschaft, a renowned pharmaceutical company at the forefront of cutting-edge research and development. His dedication to enhancing pharmaceutical technologies has propelled Bayer Pharma Aktiengesellschaft to new heights of innovation and excellence.

Collaborations:

In his quest for groundbreaking discoveries, Grunenberg has collaborated closely with esteemed colleagues such as Johannes Platzek and Gunnar Garke. Together, they have synergized their talents and expertise to drive forward pioneering advancements in pharmaceutical science.

Conclusion:

In conclusion, Alfons Grunenberg's remarkable journey as an inventor exemplifies the power of creativity and perseverance in driving meaningful change within the pharmaceutical industry. His legacy serves as a beacon of inspiration for aspiring inventors and underscores the transformative impact of innovation in shaping the future of healthcare.

Profile summary based on public USPTO records.